Granisol (granisetron hydrochloride) NDC 80056-801

NDC codes

FDA NDC Directory

Product NDC (as listed)80056-801Labeler and product segments. Claims need a package NDC.

Product NDC at billing width80056-0801Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
80056-801-30	80056080130	30 mL in 1 BOTTLE, GLASS (80056-801-30)Marketed from Jul 4, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Granisol
Generic name (nonproprietary): granisetron hydrochloride
Active ingredients: Granisetron hydrochloride — 2 mg/10mL
Dosage form: Solution
Route: Oral
Labeler: Intra-Sana Laboratories
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 219282
Marketing start: Jul 4, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Serotonin 3 Receptor Antagonists (Mechanism)
Identifiers: Product ID 80056-801_30daad07-468f-c766-e063-6294a90a0019SPL ID 30daad07-468f-c766-e063-6294a90a0019SPL set ID 2758eb4d-2fe0-4f74-b3f5-b4903009e97cRxCUI 251426, 763507UNII 318F6L70J8
Pharmacologic class: Serotonin-3 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N480056080130 followed by a unit qualifier and the quantity

Package 80056-0801-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 21, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Granisetron is indicated for the prevention of: Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)